Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Low-intensity cytoreduction with low-dose cytarabine prior to blinatumomab for pediatric and AYA R/R ALL integrated with multi-omics analysis to discover predictive biomarkers: Initial results from JPLSG-ALL-R19-blin

View Full Paper
Ask AI
Bookmark
Share

Authors

IKItaru KatoHKHirokazu KobushiASAkiko Saito

Discussion

Loading...

Member takes

Overview

Phase I/II trial found a 50% overall response in pediatric B-ALL, suggesting low-intensity treatment may optimize therapy.

Key Points

  • Half of the 20 enrolled patients responded to treatment with blinatumomab after low-dose cytarabine.
  • Mass cytometry and gut microbiota analysis established potential predictive links to treatment outcomes.
  • Study involved pediatric patients with relapsed or refractory B-ALL requiring less toxic therapies.
  • Future personalized immunotherapy approaches may benefit from integrated analyses of immune and microbiome factors.

Cite This Study

Kato et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236deadhttps://doi.org/10.1182/blood-2025-1583
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of blinatumomab as frontline treatment for infant acute lymphoblastic leukemia2025
  2. 2Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity2025
  3. 3Blinatumomab demonstrates MRD eradication in MRD-positive/chemotherapy-delayed pediatric B-ALL and high response in relapsed/refractory cases: a multicenter cohort study2025
  4. 4Blinatumomab vs. chemotherapy in pediatrics B-cell ALL: A meta-analysis of randomized controlled trials2025
  5. 5Blinatumomab mitigates the impact of traditional adverse prognosticators among children with standard risk b-acute lymphoblastic leukemia: Updated results of the Children's oncology group (COG) Trial AALL17312025